On June 28, 2017, Nokia will cooperate with China Mobile Communications Corporation (“China Mobileâ€) to demonstrate at the Shanghai World Mobile Conference how 5G can provide strong support for telemedicine services and significantly improve the level of emergency patient care services. And efficiency, and then promote industrial change.
5G will use network slicing technology, which enables operators to meet the diverse needs of different customers and services for latency, speed and capacity. During the Shanghai Mobile World Congress, Nokia and China Mobile will end on 5G network technology Slice how to meet the high reliability requirements such as emergency support telemedicine applications on display in China Mobile booth.
The demonstration will use technologies such as Nokia's 5G FIRST solution to support independently deployed NR base stations, service-based next-generation core networks, and service flow-based QoS to ensure that ambulances and hospital staff are supersonic in the delivery of emergency patients. High-rate, very low latency real-time communication. The high-speed communication capability of 5G wireless air interface and refined QoS guarantee and network slicing technology can ensure high-bandwidth images such as patient X-ray film and video are transmitted to the hospital in real time. The doctor will be able to diagnose and prepare for the patient's transit, and gain valuable time to treat the patient.
Yu Xiaotong, head of China Mobile's customer business team in Greater China, said: "We are very pleased to work with China Mobile to provide people with a more complete, usable and efficient telemedicine solution through 5G technology. As a 5G technology The leader of the field, Nokia is committed to the R&D, practice and application of 5G technology, using high-tech means to facilitate people's lives and expand the infinite possibilities of human beings."
Respiratory disease is a common disease, frequently-occurring disease, the main lesion in the trachea, bronchi, lung and chest, lesions are more cough, chest pain, respiratory effects, severe breathing difficulties, hypoxia, and even respiratory failure and death. Due to air pollution, smoking and other factors, The chronic obstructive pulmonary disease is increasing including chronic bronchitis, emphysema, pulmonary heart disease, bronchial asthma, lung cancer, pulmonary diffuse interstitial fibrosis, and pulmonary infection the morbidity and mortality of the disease at home and abroad . Therefore, anti-respiratory disease drugs are also more and more attention paid by researchers. Respiratory disease have the symptoms of cough, sputum, hemoptysis, chest pain, shortness of breath and other symptoms of lack of specificity, often clinicians mistaken by people for colds, bronchitis, and severe pneumonia, tuberculosis or lung cancer and other diseases delayed diagnosis; Respiratory tract infection, to be developed to emphysema, pulmonary heart disease, respiratory failure was taken seriously, but it was too late, its pathology and physiological function has been difficult to reverse. As with other systemic diseases, careful and detailed medical history and physical examination are the basis for the diagnosis of respiratory diseases, and should be combined with routine laboratory tests and other special findings to conduct a comprehensive and comprehensive analysis. Currently the most clinical application of anti-respiratory disease drugs have the following four categories: 1. Antihistamines 2. Cough medicine 3. Bronchodilator 4. Expectorant 5. Anti-asthma drugs.
Anti-asthma Drugs, Antitussives, Expectorants, β adrenergic receptor agonists, M Cholinergic Blockers, Phosphodiesterase Inhibitors, Anti-Respiratory Drugs,Respiratory System Diseases Treatment
Taizhou Volsen Chemical Co., Ltd. , https://www.volsenchem.com